A Phase 3, Randomised, Double-blind Trial (TARGET) Ceftobiprole Compared With Vancomycin Plus Aztreonam In ... - Physician's Weekly

Development of new broad-spectrum antibiotics that are effective against both gram-positive and gram-negative bacteria could improve treatment choices for bacterial skin and skin structure infections (ABSSSIs). Ceftobiprole is an advanced-generation intravenous cephalosporin that has extensive in vitro efficacy against both gram-positive and gram-negative bacteria (including methicillin-resistant Staphylococcus aureus). The TARGET study compared ceftobiprole to vancomycin + aztreonam in a randomized, double-blind, active-controlled, parallel-group, multicenter, phase 3 noninferiority trial. Early clinical response 48–72 hours after treatment initiation in the intent-to-treat (ITT) population was the primary efficacy endpoint defined by the Food and Drug Administration. In contrast, the European Medicines Agency defined investigator-assessed clinical success at the test-of-cure (TOC) visit. The lower limit of the 95% CI for the difference in success rates (ceftobiprole versus vancomycin/aztreonam more than −10%) was considered noninferiority. Adverse event reporting and laboratory data collection were used to assess safety. Ceftobiprole (n=335) or vancomycin/aztreonam (n=344) were given to a total of 679 patients. Early clinical success rates in the ceftobiprole and vancomycin/aztreonam groups were 91.3% and 88.1%, respectively, with noninferiority (adjusted difference: 3.3%; 95% CI: 1.2, 7.8). Noninferiority was demonstrated for both the ITT (90.1% vs. 89.0%) and clinically evaluable (97.9% vs. 95.2%) populations, and investigator-assessed clinical success at the TOC visit was similar across the 2 groups. Microbiological success and safety profiles were similar in both treatment groups. In terms of early clinical response and investigator-assessed clinical outcome at the TOC visit, TARGET showed that ceftobiprole is non-inferior to vancomycin/aztreonam in the treatment of ABSSSIs.  

Link:academic.oup.com/cid/article/73/7/e1507/5902794 

Adblock test (Why?)

Comments

Post a Comment

Popular posts from this blog

Rashes that look like scabies: Causes, symptoms, and treatment - Medical News Today

Image
Scabies is a skin condition that occurs as the result of a mite known as Sarcoptes scabiei. The rash that results from scabies may appear similar to other skin conditions, such as psoriasis, eczema, or contact dermatitis. In this article, we look at what a scabies rash looks like. We also look at other rashes that are similar in appearance and their treatment options. Scabies is a common condition that occurs as the result of an infestation of a microscopic skin mite called Sarcoptes scabiei. The mites burrow under the skin, causing intense itching and a rash. The Centers for Disease Control and Prevention (CDC) describes the rash as pimple-like. On darker skin, the rash may be more difficult to see, but a person should be able to feel it. According to DermNet, a scabies rash is varied in appearance, and may appear as: pimple-like on the limbs and trunk widespread or coin-shaped small blisters scales lesions in the armpits, groin, navel, areolas, scrotum, buttocks, and along the penil...
Read more

Urinary Tract Infection (UTI): Causes, Symptoms & Treatment - Cleveland Clinic

Image
Can I prevent a urinary tract infection? The following lifestyle changes can help prevent urinary tract infections: Practice good hygiene Practicing good hygiene is one of the best ways to help prevent UTIs. This is especially important if you have a vagina because your urethra is much shorter, and it's easier for E. coli to move from your rectum back into your body. Always wipe from front to back after a bowel movement (pooping) to avoid this. During your menstrual cycle, it's also a good idea to regularly change your period products, including pads and tampons. You should also avoid using any deodorants on your vagina. Drink plenty of fluids Drinking extra fluids — especially water — each day can help flush out bacteria from your urinary tract. Healthcare providers recommend drinking six to eight glasses of water daily. Change your peeing habits Peeing can play a big role in getting rid of bacteria from your body. Your pee is a waste product, and each time you empty your bla...
Read more

Symtuza: Uses, side effects, alternatives, and more - Medical News Today

Image
The Food and Drug Administration (FDA) approves prescription drugs such as Symtuza to treat certain conditions. Symtuza is FDA-approved to treat HIV-1 in adults and children who weigh at least 40 kilograms (kg), which is about 88 pounds (lb). It's approved for people who: have just been diagnosed with HIV and haven't started treatment yet, OR are changing from another HIV treatment and: have been on a stable antiretroviral regimen for at least 6 months (this means you haven't had any changes to your HIV drugs for at least 6 months) have a viral load (the amount of HIV in your blood) that's less than 50 copies per milliliter (mL) have HIV that doesn't have mutations (changes) that could make it resistant (less likely to respond) to darunavir or tenofovir (two of the active drugs in Symtuza) HIV explained HIV stands for human immunodeficiency virus. There are two forms of this virus, HIV-1 and HIV-2. HIV-1 is the most common form. HIV is transmitted through body fluid...
Read more